Central effects of GLP-1: New opportunities for treatments of neurodegenerative diseases

Journal of Endocrinology

Volumn 221, Issue 1, 2014, Pages

  Hölscher, Christian ^a  

^a LANCASTER UNIVERSITY   (United Kingdom)

Author keywords

Alzheimer's disease; Amyotrophic lateral sclerosis; Glucagon like peptide 1; Incretins; Ischaemia; Multiple sclerosis; Neurodegeneration; Parkinson's disease; Stroke

Indexed keywords

AMYLOID BETA PROTEIN; DOPAMINE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INSULIN; LIRAGLUTIDE; LIXISENATIDE;

ALZHEIMER DISEASE; AMYLOID PLAQUE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BASAL GANGLION; BLOOD BRAIN BARRIER; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CHRONIC INFLAMMATION; DEGENERATIVE DISEASE; DOPAMINERGIC NERVE CELL; HUMAN; LONG TERM POTENTIATION; MEMORY DISORDER; MOTOR ACTIVITY; MOTOR CONTROL; MOTOR PERFORMANCE; MULTIPLE SCLEROSIS; NERVE CELL PLASTICITY; NERVE FIBER GROWTH; NERVE REGENERATION; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PARKINSON DISEASE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; SUBSTANTIA NIGRA; SYNAPSE; SYNAPTIC TRANSMISSION;

ALZHEIMER'S DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; GLUCAGON-LIKE PEPTIDE 1; INCRETINS; ISCHAEMIA; MULTIPLE SCLEROSIS; NEURODEGENERATION; PARKINSON'S DISEASE; STROKE;

ANIMALS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS;

EID: 84897848470     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-13-0221     Document Type: Article

References (99)

1. Aharoni R, Vainshtein A, Stock A, Eilam R, From R, Shinder V&Arnon R 2011 Distinct pathological patterns in relapsing-remitting and chronic models of experimental autoimmune enchephalomyelitis and the neuroprotective effect of glatiramer acetate. Journal of Autoimmunity 37 228-241
2. Aisen PS 2002 The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease. Lancet Neurology 1 279-284
3. Arakawa M, Mita T, Azuma K, Ebato C, Goto H, Nomiyama T, Fujitani Y, Hirose T, Kawamori R & Watada H 2010 Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 59 1030-1037
4. Arnon R & Aharoni R 2009 Neuroprotection and neurogeneration in MS and its animal model EAE effected by glatiramer acetate. Journal of Neural Transmission 116 1443-1449
5. Aviles-Olmos I, Limousin P, Lees A & Foltynie T 2012 Parkinson's disease, insulin resistance andnovel agents ofneuroprotection. Brain136374-384
6. Aviles-Olmos I, Dickson J, Kefalopoulou Z,Djamshidian A, Ell P, Soderlund T, Whitton P,Wyse R, Isaacs T, Lees A et al. 2013 Exenatide and the treatment of patients with Parkinson's disease. Journal of Clinical Investigation 123 2730-2736
7. Ayasolla K, Khan M, Singh AK & Singh I 2004 Inflammatory mediator and b-amyloid (25-35)-induced ceramide generation and iNOS expression are inhibited by vitamin E. Free Radical Biology & Medicine 37 325-338
8. Azzouz M, Ralph GS, Storkebaum E, Walmsley LE, Mitrophanous KA, Kingsman SM, Carmeliet P & Mazarakis ND 2004 VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 429 413-417
9. Bayliss W & Starling E 1902 On the causation of the so-called 'peripheral reflex secretion' of the pancreas. Proceedings of the Royal Society of London, Series B: Biological Sciences 69 352-252
10. Benomar Y, Naour N, Aubourg A, Bailleux V, Gertler A, Djiane J, Guerre-Millo M & Taouis M 2006 Insulin and leptin induce Glut4 plasma membrane translocation and glucose uptake in a human neuronal cell line by a phosphatidylinositol 3-kinase-dependent mechanism. Endocrinology 147 2550-2556
11. BertilssonG, Patrone C, ZachrissonO, Andersson A, Dannaeus K, Heidrich J, Kortesmaa J, Mercer A, Nielsen E, Ronnholm H et al. 2008 Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease. Journal of Neuroscience Research 86 326-338
12. Biessels GJ, Bravenboer B & Gispen WH 2004 Glucose, insulin and the brain: modulation of cognition and synaptic plasticity in health and disease: a preface. European Journal of Pharmacology 490 1-4
13. Biessels GJ, De Leeuw FE, Lindeboom J, Barkhof F & Scheltens P 2006 Increased cortical atrophy in patients with Alzheimer's disease and type 2 diabetes mellitus. Journal of Neurology, Neurosurgery, and Psychiatry 77 304-307
14. Bradbury J 2005 Hope for AD with NGF gene-therapy trial. Lancet Neurology 4 335
15. Campbell JE & Drucker DJ 2013 Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metabolism 17 819-837
16. Carro E & Torres-Aleman I 2004a The role of insulin and insulin-like growth factor I in the molecular and cellular mechanisms underlying the pathology of Alzheimer's disease. European Journal of Pharmacology 490 127-133
17. Carro E & Torres-Aleman I 2004b Insulin-like growth factor I and Alzheimer's disease: therapeutic prospects? Expert Review of Neurotherapeutics 4 79-86
18. Cole GM, Morihara T, Lim GP, Yang F, Begum A & Frautschy SA 2004 NSAID and antioxidant prevention of Alzheimer's disease: lessons from in vitro and animal models. Annals of the New York Academy of Sciences 1035 68-84
19. Cotman CW, Berchtold NC & Christie LA 2007 Exercise builds brain health: key roles of growth factor cascades and inflammation. Trends in Neurosciences 30 464-472
20. Courreges JP, Vilsboll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Verhoeven R, Buganova I & Madsbad S 2008 Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with type 2 diabetes. Diabetic Medicine 25 1129-1131
21. Craft S 2007 Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment. Current Alzheimer Research 4 147-152
22. Craft S 2010 A randomized, placebo-controlled trial of intranasal insulin in amnestic MCI and early Alzheimer's. In ICAD Conference, pp abstr P3-455. Hawaii, USA
23. van Dam P & Aleman A 2004 Insulin-like growth factor-I, cognition and brain aging. European Journal of Pharmacology 490 87-95
24. Dozier KC, Cureton EL, Kwan RO, Curran B, Sadjadi J & Victorino GP 2009 Glucagon-like peptide-1 protects mesenteric endothelium from injury during inflammation. Peptides 30 1735-1741
25. Drucker DJ & NauckMA 2006 The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368 1696-1705
26. During MJ, Cao L, Zuzga DS, Francis JS, Fitzsimons HL, Jiao X, Bland RJ, Klugmann M, Banks WA, Drucker DJ et al. 2003 Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nature Medicine 9 1173-1179
27. Egefjord L, Gejl M, Moller A., Braendgaard H, GottrupH, Antropova O, Moller N, Poulsen HE, Gjedde A, Brock B et al. 2012 Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer s disease - protocol for a controlled, randomized double-blinded trial. Danish Medical Journal 59 A4519
28. Elkinson S & Keating GM 2013 Lixisenatide: first global approval. Drugs 73 383-391
29. Freiherr J, HallschmidM, FreyWHII, Brunner YF,Chapman CD, Holscher C, Craft S,De Felice FG&Benedict C 2013 Intranasal insulin as a treatment for Alzheimer's disease: a review of basic research and clinical evidence CNS Drugs 27 505-514
30. Gault V & Holscher C 2008 GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by b-amyloid. European Journal of Pharmacology 587 112-117
31. Gengler S, McClean P,McCurtin R, Gault V & Holscher C 2012 Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice. Neurobiology of Aging 33 265-276
32. Gregory-Evans K, Chang F, Hodges MD & Gregory-Evans CY 2009 Ex vivo gene therapy using intravitreal injection of GDNF-secreting mouse embryonic stem cells in a rat model of retinal degeneration. Molecular Vision 15 962-973
33. Griffin WS 2008 Perispinal etanercept: potential as an Alzheimer therapeutic Journal of Neuroinflammation 5 3
34. Grillo CA, Piroli GG, Hendry RM & Reagan LP 2009 Insulin-stimulated translocation of GLUT4 to the plasmamembrane in rat hippocampus is PI3-kinase dependent. Brain Research 1296 35-45
35. Haan MN 2006 Therapy insight: type 2 diabetes mellitus and the risk of late-onset Alzheimer's disease. Nature Clinical Practice. Neurology 2 159-166
36. Hamilton A & Holscher C 2009 Receptors for the insulin-like peptide GLP-1 are expressed on neurons in the CNS. Neuroreport 20 1161-1166
37. Hamilton A, Patterson S, Porter D, Gault VA & Holscher C 2011 Novel GLP-1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain. Journal of Neuroscience Research 89 481- 489
38. Han W-N, Holscher C, Yuan L, Yang W, Wang X-h, Wu M-N & Qi J-S 2013 Liraglutide protects against b-amyloid induced impairment of spatial learning and memory in rats. Neurobiology of Aging 32 576-588
39. Harkavyi A, Abuirmeileh A, Lever R, Kingsbury AE, Biggs CS & Whitton PS 2008 Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease. Journal of Neuroinflammation 5 19
40. Himeno T, Kamiya H, Naruse K, Harada N, Ozaki N, Seino Y, Shibata T, Kondo M, Kato J, Okawa T et al. 2011 Beneficial effects of exendin-4 on experimental polyneuropathy in diabetic mice. Diabetes 60 2397-2406
41. Hölscher C 1999 Synaptic plasticity and learning and memory: LTP and beyond. Journal of Neuroscience Research 58 62-75
42. Holscher C 2005 Development of b-amyloid-induced neurodegeneration in Alzheimer's disease and novel neuroprotective strategies. Reviews in the Neurosciences 16 181-212
43. Holscher C 2010 Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer's disease. Recent Patents on CNS Drug Discovery 5 109-117
44. Holscher C 2011 Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease. Biochemical Society Transactions 39 891-897
45. Holscher C & Li L 2010 New roles for insulin-like hormones in neuronal signalling and protection: new hopes for novel treatments of Alzheimer's disease? Neurobiology of Aging 31 1495-1502
46. Holst JJ 2004 Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors. Expert Opinion on Emerging Drugs 9 155-166
47. Hoyer S 1997 Models of Alzheimer's disease: cellular and molecular aspects Journal ofNeuralTransmission 49 11-21
48. Hoyer S 2004 Glucose metabolism and insulin receptor signal transduction in Alzheimer's disease. European Journal of Pharmacology 490 115-125
49. Hunter K & Holscher C 2012 Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis BMC Neuroscience 13 33-38
50. Iwai T, Ito S, Tanimitsu K, Udagawa S & Oka J 2006 Glucagon-like peptide-1 inhibits LPS-induced IL-1b production in cultured rat astrocytes Neuroscience Research 55 352-360
51. Janson J, Laedtke T, Parisi JE, O'Brien P, Petersen RC & Butler PC 2004 Increased risk of type 2 diabetes in Alzheimer's disease. Diabetes 53 474-481
52. Kastin AJ & Akerstrom V 2003 Entry of exendin-4 into brain is rapid but may be limited at high doses. International Journal of Obesity and Related Metabolic Disorders 27 313-318
53. Kastin AJ, Akerstrom V & Pan W 2002 Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. Journal of Molecular Neuroscience 18 7-14
54. Knippenberg S, Thau N, Dengler R, Brinker T & Petri S 2012 Intracerebroventricular injection of encapsulated human mesenchymal cells producing glucagon-like peptide-1 prolongs survival in a mouse model of ALS. PLoS ONE 7 e36857
55. Kuipers SD & Bramham CR 2006 Brain-derived neurotrophic factor mechanisms and function in adult synaptic plasticity: new insights and implications for therapy. Current Opinion in Drug Discovery & Development 9 580-586
56. Kunst C 2004 Complex genetics of amyotrophic lateral sclerosis. American Journal of Human Genetics 75 933-947
57. Lee YJ, Han SB, Nam SY, Oh KW & Hong JT 2010 Inflammation and Alzheimer's disease. Archives of Pharmacal Research 33 1539-1556
58. Lee CH, Yan B, Yoo KY, Choi JH, Kwon SH, Her S, Sohn Y, Hwang IK, Cho JH, Kim YM et al. 2011 Ischemia-induced changes in glucagon-like peptide-1 receptor and neuroprotective effect of its agonist, exendin-4, in experimental transient cerebral ischemia. Journal of Neuroscience Research 89 1103-1113
59. Leibson CL, Rocca WA, Hanson VA, Cha R, Kokmen E, O'Brien PC & Palumbo PJ 1997 Risk of dementia among persons with diabetes mellitus: a population-based cohort study. American Journal of Epidemiology 145 301-308
60. Lester-Coll N, Rivera EJ, Soscia SJ, Doiron K, Wands JR & de la Monte SM 2006 Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease. Journal of Alzheimer's Disease 9 13-33
61. Li L & Hölscher C 2007 Common pathological processes in Alzheimer's disease and type 2 diabetes: a review. Brain Research Reviews 56 384-402
62. Li Y, Perry T, Kindy MS, Harvey BK, Tweedie D, Holloway HW, Powers K, Shen H, Egan JM, Sambamurti K et al. 2009 GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. PNAS 106 1285-1290
63. Li Y, Duffy K, Ottinger M, Ray B, Bailey J, Holloway H, Tweedie D, Perry T, Mattson M, Kapogiannis D et al. 2010 GLP-1 receptor stimulation reduces amyloid-b peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. Journal of Alzheimer's Disease 19 1205-1219
64. Li Y, Chigurupati S, Holloway HW, Mughal M, Tweedie D, Bruestle DA, Mattson MP, Wang Y, Harvey BK, Ray B et al. 2012 Exendin-4 ameliorates motor neuron degeneration in cellular and animal models of amyotrophic lateral sclerosis. PLoS ONE 7 e32008
65. Luchsinger JA, Tang MX, Shea S & Mayeux R 2004 Hyperinsulinemia and risk of Alzheimer's disease. Neurology 63 1187-1192
66. Madsbad S, Kielgast U, Asmar M, Deacon C, Torekov SS & Holst JJ 2011 An overview of once-weekly GLP-1 receptor agonists - available efficacy and safety data and perspectives for the future. Diabetes, Obesity & Metabolism 13 394-407
67. McClean P, Parthsarathy V, Faivre E & Hölscher C 2011 The diabetes drug Liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease. Journal of Neuroscience 31 6587-6594
68. McGovern S, Kerry H & Holscher C 2012 Effects of the glucagon-like polypeptide-1 analogue (Val8)GLP-1 on learning, progenitor cell proliferation and neurogenesis in the C57B/16 mouse brain. Brain Research 1473 204-213
69. Moloney AM, Griffin RJ, Timmons S, O'Connor R, Ravid R & O'Neill C 2010 Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling Neurobiology of Aging 31 224-243
70. de la Monte SM & Wands JR 2006 Molecular indices of oxidative stress and mitochondrial dysfunction occur early and often progress with severity of Alzheimer's disease. Journal of Alzheimer's Disease 9 167-181
71. Moroo I, Yamada T, Makino H, Tooyama I, McGeer PL, McGeer EG & Hirayama K 1994 Loss of insulin receptor immunoreactivity from the substantia nigra pars compacta neurons in Parkinson's disease. Acta Neuropathologica 87 343-348
72. Morris JK, Zhang H, Gupte AA, Bomhoff GL, Stanford JA & Geiger PC 2008 Measures of striatal insulin resistance in a 6-hydroxydopamine model of Parkinson's disease. Brain Research 1240 185-195
73. Morris JK, Bomhoff GL, Gorres BK, Davis VA, Kim J, Lee PP, Brooks WM, Gerhardt GA, Geiger PC & Stanford JA 2011 Insulin resistance impairs nigrostriatal dopamine function. Experimental Neurology 231 171-180
74. Nauck MA 2011 Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. American Journal of Medicine 124 S3-18
75. Ohara T, Doi Y, Ninomiya T, Hirakawa Y, Hata J, Iwaki T, Kanba S & Kiyohara Y 2011 Glucose tolerance status and risk of dementia in the community: the Hisayama Study. Neurology 77 1126-1134
76. Okereke OI, Selkoe DJ, Pollak MN, Stampfer MJ, Hu FB, Hankinson SE & Grodstein F 2008 A profile of impaired insulin degradation in relation to late-life cognitive decline: a preliminary investigation. International Journal of Geriatric Psychiatry 24 177-182
77. Parsarathy V & Holscher C 2011 The novel GLP1 analogue, Liraglutide, reduces inflammation in a mouse model of brain tissue injury. In Society for Neuroscience Annual Meeting. Washington, DC
78. Perry T & Greig NH 2005 Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer's disease Current Alzheimer Research 2 377-385
79. Perry T, Haughey NJ, Mattson MP, Egan JM & Greig NH 2002 Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. Journal of Pharmacology and Experimental Therapeutics 302 881-888
80. Perry T, Lahiri DK, Sambamurti K, Chen D, Mattson MP, Egan JM & Greig NH 2003 Glucagon-like peptide-1 decreases endogenous amyloid-b peptide (Ab) levels and protects hippocampal neurons from death induced by Ab and iron. Journal of Neuroscience Research 72 603-612
81. Perry T, Holloway HW, Weerasuriya A,Mouton PR, Duffy K,Mattison JA & GreigNH 2007 Evidence ofGLP-1-mediatedneuroprotection inan animal modelofpyridoxine-inducedperipheral sensoryneuropathy. Experimental Neurology 203 293-301
82. Porter DW, Irwin N, Flatt PR, Holscher C & Gault VA 2010a Prolonged GIP receptor activation improves cognitive function, hippocampal synaptic plasticity and glucose homeostasis in high-fat fed mice. European Journal of Pharmacology 650 688-693
83. Porter DW, Kerr BD, Flatt PR, Holscher C & Gault VA 2010b Four weeks administration of Liraglutide improves memory and learning as well as glycaemic control in mice with high fat dietary-induced obesity and insulin resistance. Diabetes, Obesity & Metabolism 12 891-899
84. Pressley JC, Louis ED, Tang MX, Cote L, Cohen PD, Glied S & Mayeux R 2003 The impact of comorbid disease and injuries on resource use and expenditures in Parkinsonism. Neurology 60 87-93
85. Reger MA, Watson GS, Green PS, Baker LD, Cholerton B, Fishel MA, Plymate SR, Cherrier MM, Schellenberg GD, Frey WH II et al. 2008a Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-b in memory-impaired older adults Journal of Alzheimer's Disease 13 323-331
86. Reger MA, Watson GS, Green PS, Wilkinson CW, Baker LD, Cholerton B, Fishel MA, Plymate SR, Breitner JC, DeGroodtWet al. 2008b Intranasal insulin improves cognition and modulates b-amyloid in early AD Neurology 70 440-448
87. Ristow M 2004 Neurodegenerative disorders associated with diabetes mellitus. Journal of Molecular Medicine 82 510-529
88. Rossi S, Furlan R, De Chiara V, Motta C, Studer V, Mori F, Musella A, Bergami A, Muzio L, Bernardi G et al. 2012 Interleukin-1b causes synaptic hyperexcitability in multiple sclerosis. Annals of Neurology 71 76-83
89. Steen E, Terry BM, Rivera E, Cannon JL, Neely TR, Tavares R, Xu XJ, Wands JR & de la Monte SM 2005 Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease - is this type 3 diabetes? Journal of Alzheimer's Disease 7 63-80
90. Stockhorst U, de Fries D, Steingrueber HJ & Scherbaum WA 2004 Insulin and the CNS: effects on food intake, memory, and endocrine parameters and the role of intranasal insulin administration in humans. Physiology & Behavior 83 47-54
91. Strachan MW 2005 Insulin and cognitive function in humans: experimental data and therapeutic considerations. Biochemical Society Transactions 33 1037-1040
92. Talbot K, Wang HY, Kazi H, Han LY, Bakshi KP, Stucky A, Fuino RL, Kawaguchi KR, Samoyedny AJ, Wilson RS et al. 2012 Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline Journal of Clinical Investigation 122 1316-1338
93. Teramoto S, Miyamoto N, Yatomi K, Tanaka Y, Oishi H, Arai H, Hattori N & Urabe T 2011 Exendin-4, a glucagon-like peptide-1 receptor agonist, provides neuroprotection in mice transient focal cerebral ischemia Journal of Cerebral Blood Flow and Metabolism 31 1696-1705
94. Ussher JR & Drucker DJ 2012 Cardiovascular biology of the incretin system Endocrine Reviews 33 187-215
95. Wang XH, Li L, Holscher C, Pan YF, Chen XR & Qi JS 2010 Val8-glucagonlike peptide-1 protects against Ab1-40-induced impairment of hippocampal late-phase long-term potentiation and spatial learning in rats Neuroscience 170 1239-1248
96. Wang MD, Huang Y, Zhang GP, Mao L, Xia YP, Mei YW & Hu B 2012 Exendin-4 improved rat cortical neuron survival under oxygen/glucose deprivation through PKA pathway. Neuroscience 226 388-396
97. Watson GS & Craft S 2004 Modulation of memory by insulin and glucose: neuropsychological observations in Alzheimer's disease. European Journal of Pharmacology 490 97-113
98. Zhao AZ, Shinohara MM, Huang D, Shimizu M, Eldar-Finkelman H, Krebs EG, Beavo JA & Bornfeldt KE 2000 Leptin induces insulin-like signaling that antagonizes cAMP elevation by glucagon in hepatocytes Journal of Biological Chemistry 275 11348-11354
99. Zhao WQ, Chen H, Quon MJ & Alkon DLw 2004 Insulin and the insulin receptor in experimental models of learning and memory. European Journal of Pharmacology 490 71-81